Sab Biotherapeutics Inc (SABS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 0 | 263 | 945 | 305 | 1,267 |
| Gross Profit | N/A | 263 | 945 | 305 | 1,267 |
| Operating Expenses | 11,309 | 10,465 | 12,335 | 19,179 | 6,590 |
| Operating Income | -11,309 | -10,202 | -11,391 | -18,874 | -5,323 |
| Interest Expense | 78 | 93 | 76 | 78 | 70 |
| Other Income | 1,038 | 2,959 | 6,441 | -3,905 | 290 |
| Pre-tax Income | -10,349 | -7,336 | -5,026 | -22,857 | -5,102 |
| Net Income Continuous | -10,349 | -7,336 | -5,026 | -22,857 | -5,102 |
| Net Income | $-10,349 | $-7,336 | $-5,026 | $-22,857 | $-5,102 |
| EPS Basic Total Ops | -1.12 | -0.79 | -0.54 | -3.85 | -0.97 |
| EPS Basic Continuous Ops | -1.12 | -0.79 | -0.54 | -3.84 | -0.97 |
| EPS Diluted Total Ops | -1.12 | -0.79 | -0.54 | -3.85 | -0.97 |
| EPS Diluted Continuous Ops | -1.12 | -0.79 | -0.54 | -3.84 | -0.97 |
| EPS Diluted Before Non-Recurring Items | -1.12 | -0.79 | -0.54 | N/A | N/A |
| EBITDA(a) | $-10,391 | $-9,232 | $-9,490 | $-17,929 | $-4,338 |